Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
0.9013
-0.0451 (-4.77%)
At close: Nov 17, 2026, 4:00 PM EST
0.8820
-0.0193 (-2.14%)
After-hours: Nov 17, 2026, 7:30 PM EST
← View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 10, 2026

Summary

SP001 is planned to enter an open-label, two-dose IgG4-RD phase II trial in Q2 2027, with runway into H2 2029. Innovent’s Sjögren’s phase Ib showed tolerability and placebo-adjusted responses across all tested doses.

Min Lee
Biotech Associate, Guggenheim

Innovation Conference. My name is Min Lee, one of the biotech associates here at the firm. It is my pleasure to welcome our next company, Spero Therapeutics. From the company, we have the President and the CEO, Esther Rajavelu. Welcome. Thanks for joining us. Why don't you make some opening comments, Esther? Maybe walk us through your company's recent history, walk us through your company's upcoming catalysts, and then we'll go to some Q&As.

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah, sure. Well, thanks, Min. Thanks for having us here. It's wonderful to participate. Spero Therapeutics is a clinical development company. We just got our first drug approved, and it's partnered with GSK, and now we are moving back to the clinic with our second agent, which is called SP001. It's an anti-CD40 ligand antibody. We in-licensed it from Innovent, announced it in July of this year, and along with it, $105 million non-recourse, non-dilutive funding to really get us into the clinic with this agent. Our lead indication is a rare disease called immunoglobulin G4-related disease, or IgG4-RD. We've guided to starting a phase II trial in that indication in the second quarter of 2027, and our runway is into the second half of 2029.

We really see this target as one where there are multiple different development opportunities, and we're looking at other development areas as well in addition to IgG4-RD.

Min Lee
Biotech Associate, Guggenheim

Wonderful. Yeah, we'll go through all of that later. How did you then first go after CD40L in particular? Was there any particular criteria that you guys were looking for when you talked with Innovent?

Esther Rajavelu
President and CEO, Spero Therapeutics

Our history has always been in-licensing assets and developing them and then deciding what to do commercially. When we started to look for the next asset as we got line of sight into a regulatory outcome for Utebzi, we were looking at a few different things. We wanted to find a target that was validated with some amount of human data, but not overcrowded and not one that was already approved. We were looking for a molecule that had some features of differentiation versus the competitive market. We also wanted to be able to take that molecule into a few different areas. The potential to deploy it into multiple different therapeutic areas or indications was something that we were interested in as well.

Min Lee
Biotech Associate, Guggenheim

Great. Okay. Maybe let's first then go through the biology of CD40 real quick. Could you maybe walk us through the history of the CD40L development? As I understand it, there have been some idiosyncratic issues with some of the earlier-gen molecules, like thrombosis, some engineering issues, some manufacturing problems. Then maybe put into perspective of how your lead asset, SP001, actually compared to these early molecules.

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah, sure. Maybe I can start with just a little bit about the target before we get into the history. CD40 ligand is an upstream immune mediator that affects both the T cells, B cells, and the antigen-presenting cells. It has the potential to really address both the innate and the adaptive immune systems. Because of that, we think there are opportunities to target diseases that are really driven by multiple different immune pathways. This target has been in research for a couple decades now. The first-gen molecules, as you say, showed evidence of clinical benefit, but there were some safety burdens, specifically the thromboembolic risk that was highlighted by ruplizumab. It was tied to the Fc region, an active Fc region that then increased the platelet risk.

Fast-forward to the second-gen molecules, which really avoided that platelet activation risk by just avoiding the antibody format. Fusion proteins and other modalities were developed. Then SP001 is what I would characterize as a third-gen molecule, which has a silent Fc region, which theoretically should avoid the thromboembolic risk of the prior generations.

Min Lee
Biotech Associate, Guggenheim

Got it. This thrombosis risk is tied to the Fc region on the antibody, not the target of CD40 or CD40L, right?

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah, exactly.

Min Lee
Biotech Associate, Guggenheim

Perfect. What about the Sanofi molecule, frexalimab? I believe you guys do actually have some preclinical data on that online. I think that's also a late-stage anti-CD40L.

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah. So, Innovent had during our diligence, we looked at a lot of the in vitro and in vivo data that Innovent had compiled, and some of these were head-to-head studies with both Amgen's and Sanofi's agents. We do share what Innovent had done, an anti-KLH in vivo mouse model and did a head-to-head study. That study demonstrated that SP001 is more potent than frexalimab, but again, all of this needs to kind of get demonstrated in the clinic.

Min Lee
Biotech Associate, Guggenheim

Does that inform anything on dosing at all?

Esther Rajavelu
President and CEO, Spero Therapeutics

No. Our dosing decisions are going to be based. I mean, it showed the potency of the molecule, but the dosing decisions would really be based on the healthy volunteer data that Innovent had compiled, as well as the Sjögren's trial that they had. The full sort of compilation of data that we have, both preclinical and clinical, would help us get to the right dose.

Min Lee
Biotech Associate, Guggenheim

Got it. Thank you. Okay, let's move on to the Sjögren's data, actually.

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah.

Min Lee
Biotech Associate, Guggenheim

I believe you guys, or Innovent actually has run a phase I-B study, I believe in China, in Sjögren's. Maybe contextualize the 16-week efficacy data that Innovent has generated in Sjögren's. How does it actually compare to some of the other precedent studies with similar baseline patient features?

Esther Rajavelu
President and CEO, Spero Therapeutics

Innovent ran a small phase I-B trial with about 30 Sjögren's patients, and they ranged from mild to moderate and severe in that scale for ESSDAI. The trial tested three doses. It was a multiple ascending dose trial. There were about 30 patients and an 8:2 active to placebo ratio. The three doses tested were 7.5, 15, and 30 mgs per kg. The primary endpoint for that trial was safety and tolerability. PK, and ESSDAI and ESSPRI were also collected as data points. That trial essentially demonstrated that the drug is tolerable across all the different doses, and it also, the PK curves were dose-dependent. The ESSDAI and ESSPRI scores are indicative in our view. Obviously, they would have to be tested in a larger phase II placebo-controlled, properly placebo-controlled trial.

What we did see was across all the doses that were tested, both on ESSDAI and ESSPRI, all three doses showed placebo-adjusted responses, and the placebo arms were worsening. There were also some biomarkers that were tested, which also trended in the right direction.

Min Lee
Biotech Associate, Guggenheim

Got it. I believe Innovent will be running a phase II Sjögren's study in 2027, I believe, right?

Esther Rajavelu
President and CEO, Spero Therapeutics

Innovent have guided to initiating a phase II by early 2027. The trial design is actually up on ClinicalTrials.gov, so I think they've made progress on that.

Min Lee
Biotech Associate, Guggenheim

Got it. Okay, one last question, and then we'll move on to the IgG4-RD. I believe there was also some cases of these upper respiratory infections across all doses compared to placebo. Could you maybe touch on this, whether this is a drug-induced effect or noise, and how are you guys watching for infections?

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah. It's an immune modulator, so some level of infection, upper respiratory infection risk is to be expected. We didn't really see a dose-dependent response on that, so it's something that we'll continue to monitor.

Min Lee
Biotech Associate, Guggenheim

Got it. Okay, thank you. Okay, let's move on to the IgG4-RD, your pipeline. I guess the big question then is, why lead with this indication given that you already had the data for Sjögren's? I mean, Sjögren's is already a bigger market than IgG4-RD. Maybe walk us through the rationale.

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah. So IgG4-RD is a really compelling area to bring a new drug, or at least test a new drug for a potential market opportunity. As you know, it's a fibroinflammatory condition. It's chronic, and untreated or undertreated, it eventually leads to organ damage. The current treatment landscape really has only one drug approved, and that's a B cell depleter. There are only a couple of other agents in development, both focused on B cells, targeting B cells. What we're attempting to bring to the patient community is a different mechanism targeting CD40 ligand, which we think could provide a broader set of benefits than what the B cells are focused on, which is flare reduction.

Min Lee
Biotech Associate, Guggenheim

Yeah. It's also more upstream, I think, right? Because you're talking about T cell, B cell, and-

Esther Rajavelu
President and CEO, Spero Therapeutics

Exactly.

Min Lee
Biotech Associate, Guggenheim

Got it. Okay. What line of treatment do you think then the CD40 could actually fit in the hierarchy of the treatment for IgG4-RD?

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah. I wouldn't sort of think of the treatment landscape as needing to be hierarchical. There are a couple of treatment objectives, right? So there is controlling the symptoms, which we would characterize as flares. There is prevention of relapse, and then there is prevention of organ damage. The first wave of therapies, as I said, are focused on flare reduction or preventing the risk of flares. Our mechanism, we believe, could go beyond just reducing flares and addressing some of the fibrotic aspects of the disease and just the progressive nature of the disease. What we're really aiming to do is provide, change the treatment landscape so that moving it away from hitting a flare and then waiting to see when the next flare comes to a chronic therapy that can be administered in a consistent manner to predictably manage patients.

Min Lee
Biotech Associate, Guggenheim

Got it. Yeah, I mean, I think that's always the sort of the next step in all of I&I. You start with autoimmunity, you quench inflammation, but next step is how do you actually reduce that long-term fibrotic effects?

Esther Rajavelu
President and CEO, Spero Therapeutics

Exactly.

Min Lee
Biotech Associate, Guggenheim

Got it. Okay, maybe let's touch on the market opportunity for the IgG4-RD. Like you said, there's only one approved drug, Amgen's UPLIZNA, the B cell depleter in IgG4-RD. How many patients have been treated so far with that drug? What's the pricing anchor, and what remains the unmet need in this space?

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah. Some of those detailed questions are great for Amgen in terms of how many patients have been treated with their drug. I'd be curious to know as well. What I can address is the unmet need left by the only approved agent. As I said, because this is a multi-organ, multifactorial disease, physicians and patients really need a therapy that helps them manage the chronic aspect of the disease that continues to progress in between flares. That's the unmet need that we're trying to manage.

Min Lee
Biotech Associate, Guggenheim

Got it. Got it. Yes, thank you. Okay. Maybe then walk us through your phase II design for the IgG4-RD.

Esther Rajavelu
President and CEO, Spero Therapeutics

The phase II trial that we are planning to initiate in the second quarter of 2027, it is an open-label phase II trial with two doses, six months of treatment duration, and the primary endpoint is IgG4-RD responder index, which is a validated tool to measure disease progression. We will also be looking for safety and tolerability signals and a few biomarkers.

Min Lee
Biotech Associate, Guggenheim

Got it. Regarding dosing, does the Sjögren's study that Innovent has conducted give you any relevant benchmark for this?

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah. I mean, there is a dosing where you would look at the Sjögren's data sets as well as the phase I healthy volunteer trials, the SAD/MAD trial that Innovent ran. I mean, this drug has been tested in about 100 human subjects. So, the compilation of those data plus the chronic tox will give us indication on dosing.

Min Lee
Biotech Associate, Guggenheim

Got it. Thank you. When it comes to the flare reduction that you guys are benchmarking, is there a particular number that you guys are anchoring it?

Esther Rajavelu
President and CEO, Spero Therapeutics

The phase II that we're running is, the primary endpoint is the responder index, and that is really what's going to drive our decision to move the trial into a phase III. As you know, the phase III registrational endpoints are tied to flare reduction. It's a little too early for us to anchor to a specific number. We need to see how we respond on what our responder index changes from baseline. There are also other biomarkers that we're going to be looking at that would really characterize this mechanism for the unmet need in this indication. All of those data points will help us decide a phase III path forward.

Min Lee
Biotech Associate, Guggenheim

Got it. When you say biomarker, I think you mentioned that there was some rheumatic factors that you were looking for, that you were looking at back in the Sjögren's study. Was there any particular IgG markers or chemokine expression markers that you guys looked at as well?

Esther Rajavelu
President and CEO, Spero Therapeutics

Well, we haven't disclosed the specific biomarkers, but yes, those are in the realm of what we would continue to look for. I mean, some of these were evidenced in the phase I-B Sjögren's trial that Innovent ran, and we'll continue to test them and test for them in our trials.

Min Lee
Biotech Associate, Guggenheim

Great. Okay. I believe right now your current drug is currently in an IV formulation. Do you guys have any plans for advancing the subq formulation into clinics soon?

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah. We will be exploring non-IV formulations.

Min Lee
Biotech Associate, Guggenheim

Okay. Okay. Maybe a real question on financials. How does your balance sheet look like, and do you guys have any guidance on the cash runway?

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah. As I said, when we announced the transaction as of June, we have our earnings in a couple days, so you will learn more. But as of June, our cash balance was about $50 million, and then we raised the $105 million from the non-dilutive, non-recourse funding. That essentially gives us runway into the second half of 2029. We think we are pretty well-positioned to deliver on IgG4-RD phase II.

Min Lee
Biotech Associate, Guggenheim

Yeah. Maybe one last question then on the market. Is there anything missing that investors currently do not get about the market for IgG4-RD? Like, how big is the market really?

Esther Rajavelu
President and CEO, Spero Therapeutics

Yeah. I mean, I think what's underappreciated by the market about IgG4-RD is just the treatment burden and how early this disease is in its evolution. There is evidence of increasing diagnostic, basically increasing rates of diagnosis. We think that as there are additional treatment options available, the landscape will evolve. Interestingly, actually just yesterday, The Lancet published new treatment guidelines. What's really interesting in the treatment guidelines that they published is for the first time, the guidelines urge physicians to begin treating as soon as the patients are diagnosed, versus in the past, it was a practice of diagnose and then watch and wait until there is a flare and treating.

The other important aspect of the guidelines that I thought was interesting is the fact that they're really asking the duration of treatment with corticosteroids to be minimized and move on to more potent treatments.

Min Lee
Biotech Associate, Guggenheim

Got it. I'll definitely have to read the paper. Thank you for reminding me. Okay, Esther, I think that's all for me.

Esther Rajavelu
President and CEO, Spero Therapeutics

Great.

Min Lee
Biotech Associate, Guggenheim

Thank you very much.

Esther Rajavelu
President and CEO, Spero Therapeutics

Thank you. Thanks for having me.